Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Advances in Pharma Business Management and Research : Volume 1 / / edited by Lars Schweizer, Theodor Dingermann, Otto Quintus Russe, Christian Jansen
| Advances in Pharma Business Management and Research : Volume 1 / / edited by Lars Schweizer, Theodor Dingermann, Otto Quintus Russe, Christian Jansen |
| Autore | Schweizer Lars |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Springer Nature, 2020 |
| Descrizione fisica | 1 online resource (X, 85 p. 11 illus.) |
| Disciplina | 615.19 |
| Soggetto topico |
Pharmaceutical technology
Health care management Health services administration Medical laws and legislation Pharmacy Pharmacy management Pharmaceutical Sciences/Technology Health Care Management Medical Law Pharmacoeconomics and Health Outcomes |
| Soggetto non controllato |
Pharmaceutical Sciences/Technology
Health Care Management Medical Law Pharmacy Pharmacoeconomics and Health Outcomes Pharmaceutics Health Care Pharmacology Pharma Management Market Access Regulatory Affairs Research & Development Quality Control Open Access Industrial chemistry & chemical engineering Health economics Medical & healthcare law Pharmacy / dispensing |
| ISBN | 3-030-35918-2 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. Introduction: Trends and developments in the pharmaceutical and life sciences industry -- Chapter 2. Relevance of instruments for measurements of Quality of Life in the AMNOG Context -- Chapter 3. The quality management system for R&D project and portfolio management in a pharmaceutical company -- Chapter 4. Brexit and Its Impact on Pharmaceutical Law - Implications for global pharma companies -- Chapter 5. Implementation of Measurable and Sustainable Actions to Improve Employee’s Engagement and Business Performance - Global Medical Clinical & Regulatory Affairs (GMCRA) – A Role Model at Fresenius Kabi -- Chapter 6. Leadership Models and Work Behavior: An Empirical Analysis of Consequences of Authentic and Transformational Leadership -- Chapter 7. Alliance Management at Merck - Establishing an operational 100-day plan for alliance launches and management. |
| Record Nr. | UNINA-9910380742003321 |
Schweizer Lars
|
||
| Springer Nature, 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antimicrobial Resistance : Global Challenges and Future Interventions / / edited by Sabu Thomas
| Antimicrobial Resistance : Global Challenges and Future Interventions / / edited by Sabu Thomas |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2020 |
| Descrizione fisica | 1 online resource (XIII, 230 p. 20 illus., 16 illus. in color.) |
| Disciplina | 615 |
| Soggetto topico |
Pharmaceutical technology
Pharmacy management Drug resistance Microbiology Pharmaceutical Sciences/Technology Pharmacoeconomics and Health Outcomes Drug Resistance Applied Microbiology Resistència als medicaments Microbiologia |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-15-3658-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1) The Evolution of Microbial Defense Systems against Antimicrobial Agents -- 2) Carbapenem Resistance in Gram-negative bacilli: Mechanisms and Challenges -- 3) Influence of Antimicrobials on the Gut Microbiota -- 4) Influence of Abiotic Factors in the Emergence of Antibiotic Resistance -- 5) Polluted Coastal and Estuarine Environments – A Potential Reservoir for AMR Determinants in Various Pathogenic Bacteria -- 6) AMR in Animal Health: Issues and One Health Solutions for LMICs -- 7) Antifungal Resistance: Current Concepts -- 8) 'Planetary Health’ Perspectives and Alternative Approaches to Tackle the AMR Challenge -- 9) Use of Bacterial Cell Wall Recycle Inhibitors to Combat AMR in Bacteria -- 10) Status quo of Omics Technologies in Analyzing the Genetic Mediators of Antimicrobial Resistance at Sub-MIC Concentrations. |
| Record Nr. | UNINA-9910416106703321 |
| Singapore : , : Springer Singapore : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Applying Comparative Effectiveness Data to Medical Decision Making : A Practical Guide / / edited by Carl Asche
| Applying Comparative Effectiveness Data to Medical Decision Making : A Practical Guide / / edited by Carl Asche |
| Edizione | [1st ed. 2016.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Adis, , 2016 |
| Descrizione fisica | 1 online resource (VIII, 113 p. 16 illus., 12 illus. in color.) |
| Disciplina | 610 |
| Soggetto topico |
Pharmacy management
Pharmacoeconomics and Health Outcomes |
| ISBN | 3-319-23329-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. Introduction to Comparative Effectiveness Research -- 2. Randomized Controlled Trials -- 3. Observational Studies -- 4. Evaluating Published CER Evidence -- 5. Epidemiological Principles Applied to CER -- 6. The Question of Value -- 7. Medical Decision Making: When Evidence and Medical Culture Clash -- 8. The Value of Prevention. |
| Record Nr. | UNINA-9910254512103321 |
| Cham : , : Springer International Publishing : , : Imprint : Adis, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Budget-Impact Analysis of Health Care Interventions : A Practical Guide / / by Josephine Mauskopf, Stephanie R. Earnshaw, Anita Brogan, Sorrel Wolowacz, Thor-Henrik Brodtkorb
| Budget-Impact Analysis of Health Care Interventions : A Practical Guide / / by Josephine Mauskopf, Stephanie R. Earnshaw, Anita Brogan, Sorrel Wolowacz, Thor-Henrik Brodtkorb |
| Autore | Mauskopf Josephine |
| Edizione | [1st ed. 2017.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Adis, , 2017 |
| Descrizione fisica | 1 online resource (224 pages) |
| Disciplina | 610.285 |
| Soggetto topico |
Pharmacy management
Medical research Health informatics Pharmacoeconomics and Health Outcomes Quality of Life Research Health Informatics |
| ISBN | 3-319-50482-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. Introduction to Budget-Impact Analysis -- 2. Determining the Analytic Framework -- 3. Estimating the Diagnosed, Treated, and Eligible Population -- 4. Estimating the Treatment Mix -- 5. Estimating Treatment-Related Costs -- 6. Estimating Condition-Related Costs -- 7. The Computing Framework and Calculations -- 8. Uncertainty Analysis -- 9. Validation -- 10. Software and Computer Interface -- 11. Reporting Budget-Impact Analyses -- 12. Additional Pragmatic Topics -- 13. Alternative Interventions -- 14. Creating Your Own Budget-Impact Analyses Today and Tomorrow. |
| Record Nr. | UNINA-9910254485803321 |
|
Mauskopf Josephine
|
||
| Cham : , : Springer International Publishing : , : Imprint : Adis, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical Epidemiology of Chronic Liver Diseases / / edited by Robert J. Wong, Robert G. Gish
| Clinical Epidemiology of Chronic Liver Diseases / / edited by Robert J. Wong, Robert G. Gish |
| Edizione | [1st ed. 2019.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 |
| Descrizione fisica | 1 online resource (349 pages) |
| Disciplina | 614.4273 |
| Soggetto topico |
Hepatology
Gastroenterology Epidemiology Pharmacy management Gastroenterology Pharmacoeconomics and Health Outcomes |
| ISBN | 3-319-94355-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Principles of Clinical Epidemiology.– Understanding Study Design for Clinical Epidemiology Studies -- Understanding the Interpretation of Disease Incidence and Prevalence -- Understanding Survival Analyses -- Epidemiology of Liver Disease – Worldwide Perspective -- Epidemiology of Liver Disease in the U.S -- Alcoholic Liver Disease -- Hepatitis B Virus – The Asian Perspective -- Hepatitis B Virus – The African Perspective -- Hepatitis B Virus – Western Perspective -- Hepatitis D Virus -- Hepatitis C Virus -- Hepatitis A and Hepatitis E Virus -- Nonalcoholic Fatty Liver Disease -- Hepatocellular Carcinoma -- Autoimmune Liver Diseases and Cholestatic Liver Diseases -- Genetic and Inherited Liver Diseases -- Cryptogenic Liver Diseases and other -- Summary. |
| Record Nr. | UNINA-9910337491903321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Controlled Substance Management in Chronic Pain : A Balanced Approach / / edited by Peter S. Staats, Sanford M. Silverman
| Controlled Substance Management in Chronic Pain : A Balanced Approach / / edited by Peter S. Staats, Sanford M. Silverman |
| Edizione | [1st ed. 2016.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2016 |
| Descrizione fisica | 1 online resource (XII, 323 p. 32 illus., 18 illus. in color.) |
| Disciplina | 616.0472 |
| Soggetto topico |
Pain medicine
Pharmacotherapy Pharmacy management Primary care (Medicine) Pain Medicine Pharmacoeconomics and Health Outcomes Primary Care Medicine |
| ISBN | 3-319-30964-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1 Scope of the pain problem -- 2 Scope of the problem: Intersection of chronic pain and addiction -- 3 Evidence-based treatment for chronic pain with opioids -- 4 Opioid pharmacology -- 5 Pharmacokinetics -- 6 Benzodiazepines, Alcohol and Stimulant Use in Combination with Opioid Use -- 7 Marijuana and cannabinoids for pain -- 8 Adjuvant agents in chronic pain therapy -- 9 Complications of opioid therapy -- 10 Risk mitigation strategies -- 11 Naloxone Treatment of Opioid Overdose -- 12 From Patient Evaluation to Opioid Overdose Prevention: Ten Steps to Make the Law Work for You and Your Patients -- 13 Treating the difficult patient -- 14 Controlled Substance Management: Exit Strategies for the Pain Practitioner -- 15 Alternatives to opiates in the management of non-cancer related pain -- Appendix A: American Society of Interventional Pain Physicians (ASIPP) Guidelines for Responsible Opioid Prescribing in Chronic Non-Cancer Pain -- Appendix B: Sample Opioid Agreement/Informed Consent -- Appendix C: Opioid Risk Tool -- Appendix D: Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP®-R) -- Appendix E: McGill Pain Questionnaire. |
| Record Nr. | UNINA-9910254556003321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cost Effectiveness Modelling for Health Technology Assessment : A Practical Course / / by Richard Edlin, Christopher McCabe, Claire Hulme, Peter Hall, Judy Wright
| Cost Effectiveness Modelling for Health Technology Assessment : A Practical Course / / by Richard Edlin, Christopher McCabe, Claire Hulme, Peter Hall, Judy Wright |
| Autore | Edlin Richard |
| Edizione | [1st ed. 2015.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Adis, , 2015 |
| Descrizione fisica | 1 online resource (XIII, 208 p. 86 illus., 3 illus. in color.) |
| Disciplina | 362.1068 |
| Soggetto topico |
Pharmacy management
Medical research Health informatics Health economics Pharmacoeconomics and Health Outcomes Quality of Life Research Health Informatics Health Economics |
| ISBN | 3-319-15744-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Acknowledgements -- Contents -- Chapter 1: Economic Evaluation, Cost Effectiveness Analysis and Health Care Resource Allocation -- 1.1 Introduction -- 1.2 Scarcity, Choice and Opportunity Cost -- 1.3 Types of Economic Evaluation -- 1.3.1 Cost Benefit Analysis (CBA) -- 1.3.2 Cost Effectiveness Analysis (CEA) -- 1.3.3 Cost Utility Analysis (CUA) -- 1.4 Incremental Cost Effectiveness Ratios (ICERs) -- 1.4.1 Simple and Extended Dominance -- 1.4.2 The Net Benefit Approach -- 1.5 Summary -- References -- Chapter 2: Finding the Evidence for Decision Analytic Cost effectiveness Models -- 2.1 Introduction -- 2.2 Choosing Resources to Search for Evidence -- 2.3 Designing Search Strategies -- 2.4 Searching for Existing Cost effectiveness Models -- 2.4.1 Where to Look -- 2.4.2 Search Strategy, Concepts, Terms and Combinations -- 2.4.3 Search Filters, Database Limits and Clinical Queries -- 2.5 Searching for Clinical Evidence -- 2.5.1 Finding the Evidence on Incidence, Prevalence and Natural History of a Disease -- 2.5.2 Finding the Evidence on the Clinical Effectiveness of Health Interventions -- 2.5.3 Database Limits and Clinical Queries -- 2.6 Finding the Evidence on Health-Related Quality of Life and Health State Preferences -- 2.6.1 Where to Look -- 2.6.2 Search Strategy, Concepts, Terms and Combinations -- 2.6.3 Search Filters, Database Limits and Clinical Queries -- 2.7 Finding Evidence on Resource Use and Costs -- 2.7.1 Where to Look -- 2.7.2 Search Strategy, Concepts, Terms and Combinations -- 2.7.3 Search Filters, Database Limits and Clinical Queries -- 2.8 Tracking and Reporting Search Activities -- 2.9 Quality Assessment Tools -- 2.10 Summary -- References -- Chapter 3: Building a Decision Tree Cost Effectiveness Model -- 3.1 Introduction -- 3.2 What Is a Decision Model? -- 3.3 Key Elements of a Decision Tree.
3.4 Costs, Benefits and Complexity -- 3.5 Exercise Building a Decision Tree -- 3.6 Summary -- References -- Chapter 4: Uncertainty, Probabilistic Analysis and Outputs from Cost Effectiveness Analyses -- 4.1 Introduction -- 4.2 Sources of Uncertainty in Cost Effectiveness Models -- 4.2.1 Sampling Variation -- 4.2.2 Extrapolation -- 4.2.3 Generalisability -- 4.2.4 Model Structure -- 4.2.5 Methodological Uncertainty -- 4.3 Analytic Responses to Uncertainty in CEA -- 4.3.1 One-Way Sensitivity Analysis -- 4.3.2 Multiway Sensitivity Analysis -- 4.3.3 Threshold Analysis -- 4.3.4 Analysis of Extremes -- 4.4 Probabilistic Sensitivity Analysis (PSA) -- 4.5 Outputs from Probabilistic Analysis -- 4.6 Some Problems with ICERs -- 4.7 Summary -- References -- Chapter 5: Introduction to Markov Cost Effectiveness Models -- 5.1 Introduction -- 5.2 Why Use Markov Models? -- 5.3 Health States -- 5.4 Transition Probabilities -- 5.5 Markov Trace -- 5.6 Cycle Length, Time Horizon and Discounting -- 5.7 Summary -- References -- Chapter 6: Probability Distributions for Effectiveness Parameters -- 6.1 Introduction -- 6.2 What Do We Mean by Effectiveness Parameters? -- 6.2.1 Obtaining Information on Effectiveness -- 6.3 Choosing Distributions for Effectiveness Parameters -- 6.3.1 Fitting a Distribution -- 6.4 Beta Distribution for Probabilities -- 6.5 Dirichlet Distribution for Multinomial Probabilities -- 6.6 Normal Distribution for Log-Relative Risk -- 6.7 Survival Analysis for Time-to-Event Data -- 6.7.1 The Exponential Distribution -- 6.7.2 The Weibull Distribution -- 6.7.3 The Gompertz Distribution -- 6.7.4 Choice of Distribution for Time-to-Event Data -- 6.8 Parameter Correlation in Survival Analysis -- 6.9 Summary -- References -- Chapter 7: Probability Distributions for Cost and Utility Parameters -- 7.1 Introduction -- 7.2 Distributions for Cost Parameters. 7.2.1 The LogNormal Distribution -- 7.2.1.1 LogNormal via Method of Moments I -- 7.2.1.2 LogNormal via Method of Moments II -- 7.2.2 The Gamma Distribution -- 7.3 Distributions for Utility Parameters -- 7.3.1 Distributional Characteristics of the Utility Scale -- 7.4 Characterising Uncertainty for Expected Utility Values Close to 1.0 -- 7.4.1 Characterising Uncertainty for Expected Utility Values Away from 1.0 -- 7.4.2 Logical Ordering for Utilities in Cost Effectiveness Models -- 7.4.3 Health State-Specific Side Effect Utility Decrements -- 7.5 Summary -- References -- Chapter 8: Correlated Parameters and the Cholesky Decomposition -- 8.1 Introduction -- 8.2 Correlated Parameters -- 8.3 Defining a Set of Correlated Parameters -- 8.4 The Cholesky Decomposition -- 8.5 What If I Need a Cholesky Decomposition for a Different Number of Variables? -- 8.6 Interpreting the Cholesky Decomposition -- 8.7 Summary -- Appendix -- Appendix 8.1: Extending the Cholesky Decomposition for More Than Three Correlated Parameters -- Chapter 9: Building a Markov Cost Effectiveness Model in Excel -- 9.1 Introduction -- 9.2 The Model -- 9.3 Modelling in Excel -- 9.4 Constructing the Parameter Table -- 9.5 Programming Your Model -- 9.6 Adding a Discount Rate, Costs and Utilities -- 9.7 Adding the Calculation of the Deterministic Incremental Cost Effectiveness Ratio (ICER) -- 9.8 Summary -- Chapter 10: Making a Markov Model Probabilistic -- 10.1 Introduction -- 10.2 Deterministic and Probabilistic Cost Effectiveness Analysis -- 10.3 Making Model Parameters Stochastic -- 10.4 Obtaining a Probabilistic Sensitivity Analysis from a Stochastic Model -- 10.5 Exercise: Probabilistic Effectiveness Parameters -- 10.6 Exercise: Probabilistic Cost and Utility Parameters -- 10.7 Exercise: Incorporating the Cholesky Decomposition -- 10.8 Summary -- Appendix. Appendix 10.1: Optimising Visual Basic Macros in Excel -- Chapter 11: Outputs from Probabilistic Sensitivity Analysis -- 11.1 Introduction -- 11.2 Scatter Plots on the Cost Effectiveness Plane -- 11.3 Cost Effectiveness Acceptability Curves (CEACs) -- 11.4 Cost Effectiveness Acceptability Frontiers (CEAFs) -- 11.5 Scatter Plots, CEACs and CEAF Exercises -- 11.6 Summary -- References -- Chapter 12: Investing in Health Care, Research and the Value of Information -- 12.1 Introduction -- 12.2 Uncertainty and Health-Care Reimbursement Decision-Making Processes -- 12.3 Investing in Innovative Health Technologies -- 12.4 Net Benefit Probability Map and Managing Decision Uncertainty -- 12.5 Delaying a Reimbursement Decision for More Research -- 12.5.1 Uncertainty in Decision Making and the Cost of Making the Wrong Decision -- 12.5.2 Expected Value of Perfect Information and the Value of Sample Information -- 12.5.3 Calculating the Expected Value of Perfect Information -- 12.6 Disaggregating the Value of Information: Expected Value of Perfect Parameter Information and the Expected Value of Sample Information -- 12.6.1 Expected Value of Perfect Parameter Information -- 12.6.2 Expected Value of Sample Information -- 12.7 Exercise: Constructing the Net Benefit Probability Map and Calculating the Value of Perfect Information -- 12.7.1 Calculating the Expected Value of Perfect Information -- 12.8 Summary -- References -- Chapter 13: Value of Information in Health Technology Regulation and Reimbursement -- 13.1 Introduction -- 13.2 Value of Information Analysis for Research Prioritisation -- 13.3 Value of Information Analysis for Research Design -- 13.3.1 Calculating the Expected Net Present Value of Sample Information -- 13.4 Is Decision Theory Ready to Inform Trial Design? -- 13.4.1 Structuring a Decision Problem. 13.4.2 Evidence Synthesis and Model Parameterisation -- 13.4.3 Computational and Statistical Challenges -- 13.4.4 Adoption by Regulatory Organisations and Reimbursement Agencies -- 13.4.5 Adoption by Public Research Commissioners and Clinical Trialists -- 13.4.6 Industrial Development of Health Technologies -- 13.5 Value of Information in the Evolving Regulatory and Reimbursement Environments -- 13.6 Summary -- Appendix -- Appendix 13.1: General Monte Carlo Sampling Algorithm for Calculation of Population ENPVSI -- References. |
| Record Nr. | UNINA-9910300166503321 |
|
Edlin Richard
|
||
| Cham : , : Springer International Publishing : , : Imprint : Adis, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Decision Making in a World of Comparative Effectiveness Research : A Practical Guide / / edited by Howard G. Birnbaum, Paul E. Greenberg
| Decision Making in a World of Comparative Effectiveness Research : A Practical Guide / / edited by Howard G. Birnbaum, Paul E. Greenberg |
| Edizione | [1st ed. 2017.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Adis, , 2017 |
| Descrizione fisica | 1 online resource (XVI, 289 p. 18 illus., 7 illus. in color.) |
| Disciplina | 615.1 |
| Soggetto topico |
Pharmacy management
Health economics Statistics Pharmaceutical technology Pharmacoeconomics and Health Outcomes Health Economics Statistics for Life Sciences, Medicine, Health Sciences Pharmaceutical Sciences/Technology |
| ISBN | 981-10-3262-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | I. Introduction -- 1. Introducing Decision Making in a World of Comparative Effectiveness Research -- 2. Perspectives on Decision Making in a World of Comparative Effectiveness: Views from Diverse Constituencies -- II. The Future of CER for Evidence Developers: Perspectives from Pharmaceutical Decision Makers -- 3. Perspectives on the Use of CER by Life Sciences Executives: An Interview with Mike Bonney -- 4. Perspectives on the Use of CER by Life Sciences Executives: An Interview with a Senior Executive at an International Life Science Company -- 5. CER: A Pharmaceutical Industry Perspective on Outlook, Dilemmas, and Controversies -- 6. Impact of Comparative Effectiveness Research on Drug Development Strategy and Innovation -- 7. Pricing of Pharmaceuticals: Current Trends and Outlook, and the Role of CER -- III. Evolving Stakeholder Considerations: Patients, Physicians, Regulators and Payers -- 8. Are Real-World Data and Evidence Good Enough to Inform Healthcare and Health Policy Decision Making? -- 9. Translating CER Evidence to Real-World Decision-Making: Some Practical Considerations -- 10. Decision Making by Public Payers -- 11. Patient and Stakeholder Engagement in Designing Pragmatic Clinical Trials -- 12. Policy Considerations: Ex-U.S. Payers and Regulators -- 13. Perspectives on the Common Drug Review (CDR) Process at the Canadian Agency for Drugs and Technologies in Health (CADTH) -- 14. Evaluating Non-Pharmaceutical Technologies at the Canadian Agency for Drugs and Technologies in Health (CADTH) -- 15. Challenges and Opportunities in the Dissemination of CER Information to Physicians and Payers: A Legal Perspective -- 16. Legal Considerations in a World of CER -- IV. Emerging Challenges, Methods and Applications of CER: Real-world and Big Data -- 17. Application of CER to Promote Adherence to Clinical Practice Guidelines -- 18. Challenges in Developing and Assessing CER for Medical Technology -- 19. Evidence Generation Using Big Data: Challenges and Opportunities -- 20. Indirect Comparisons Using Clinical Trial Data: 5 Years Later -- 21. Decision-Making with Machine Learning in Our Modern, Data-Rich Healthcare Industry. |
| Record Nr. | UNINA-9910254651303321 |
| Singapore : , : Springer Singapore : , : Imprint : Adis, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The FDA for Doctors / / by William H. Eaglstein
| The FDA for Doctors / / by William H. Eaglstein |
| Autore | Eaglstein William H |
| Edizione | [1st ed. 2014.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2014 |
| Descrizione fisica | 1 online resource (98 p.) |
| Disciplina | 353.6 |
| Soggetto topico |
Medicine
Health administration Pharmacy management Medicine/Public Health, general Health Administration Pharmacoeconomics and Health Outcomes |
| ISBN | 3-319-08362-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction - The FDA, Doctors and the Practice of Medicine -- Drugs -- Devices -- Biologics -- Combination Products -- Supplements and Neutraceuticals -- Foods -- Cosmetics and Cosmeceuticals -- The FDA (history, organization, budgets) -- The Approval Process (including Phases 1-4, advisory committees, Guidances and personal medicine) -- The FDA and Promotion and Advertising -- The FDA and Drug Names -- The FDA , Politics and the Public. |
| Record Nr. | UNINA-9910300340303321 |
|
Eaglstein William H
|
||
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Health Technology Assessment in Japan : Policy, Pharmacoeconomic Methods and Guidelines, Value, and Beyond / / by Isao Kamae
| Health Technology Assessment in Japan : Policy, Pharmacoeconomic Methods and Guidelines, Value, and Beyond / / by Isao Kamae |
| Autore | Kamae Isao |
| Edizione | [1st ed. 2019.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Adis, , 2019 |
| Descrizione fisica | 1 online resource (xvi, 269 pages) : illustrations |
| Disciplina | 338.433621 |
| Soggetto topico |
Health economics
Pharmacy management Health Economics Pharmacoeconomics and Health Outcomes |
| ISBN | 981-13-5793-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. Basics to Know -- 2. New HTA Policy in Japan -- 3. MHLW Guideline for Cost-effectiveness Analysis -- 4. How to Appraise -- 5. Exercises for Powerful Assessment -- 6. Intermediate Level Methods -- 7．Advanced Research Topics. |
| Record Nr. | UNINA-9910350219803321 |
|
Kamae Isao
|
||
| Singapore : , : Springer Singapore : , : Imprint : Adis, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
